文献速递肿瘤 PET/CT核素与放射性配体治疗

高危前列腺癌根治术前PSMA PET/CT分期与常规影像对生化无复发生存的影响:丹麦全国队列研究

Biochemical Recurrence-Free Survival After Radical Prostatectomy in Patients with High-Risk Prostate Cancer: A Nationwide Study of PSMA PET/CT Versus Conventional Imaging.
PubMed 文献 · J Nucl Med · 2026-05-01

该全国队列纳入2016—2023年接受根治性前列腺切除术的高危前列腺癌男性,比较术前PSMA PET/CT与常规影像分期者的生化无复发生存(BRFS)。PSMA PET/CT组5年BRFS为65.1%,常规影像组为61.1%,加权风险比0.82(95%CI 0.70-0.96,P=0.014);Gleason 8-10分患者差异更明显(62.5% vs 48.9%,HR 0.61,95%CI 0.51-0.74,P<0.001)。总生存也倾向PSMA PET/CT组,但随访有限。

要点

  • 高危前列腺癌根治术前PSMA PET/CT分期与更高的5年BRFS相关。
  • Gleason 8-10分患者中PSMA PET/CT组5年BRFS为62.5%,常规影像组48.9%。
  • 总生存差异因随访有限无法定论,研究为观察性设计。

核心结论

  • 高危前列腺癌根治术前使用PSMA PET/CT分期与BRFS率升高相关。

研究设计与样本

  • 丹麦全国队列研究纳入2016—2023年接受根治性前列腺切除术的高危前列腺癌男性,按术前PSMA PET/CT或常规影像分期分组。
  • 共3279例 eligible 患者,其中959例(29.3%)接受术前PSMA PET/CT。
  • 采用逆概率加权和校正Cox比例风险回归分析,主要结局为BRFS,次要结局为总生存。

主要发现

  • PSMA PET/CT组5年BRFS为65.1%(95%CI 61.4%-68.7%),常规影像组为61.1%(95%CI 58.9%-63.2%),加权HR 0.82(95%CI 0.70-0.96,P=0.014)。
  • Gleason 8-10分患者中,PSMA PET/CT组5年BRFS为62.5%(95%CI 57.7%-67.2%),常规影像组为48.9%(95%CI 44.9%-52.9%),HR 0.61(95%CI 0.51-0.74,P<0.001)。
  • PSMA PET/CT组总生存也更高,但随访时间有限,无法得出确切结论。

临床怎么用

  • 对高危前列腺癌根治术前分期,可考虑PSMA PET/CT以辅助风险分层并与BRFS改善相关。
  • Gleason 8-10分患者可能从PSMA PET/CT分期中获益更明显。

局限性

  • 研究为观察性设计,存在残余混杂可能。
  • 总生存分析因随访有限无法得出可靠结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Prostate-specific membrane antigen (PSMA) PET/CT offers excellent accuracy in the staging of high-risk prostate cancer (PCa), yet outcomes-based evidence of the clinical benefit remains limited. We aimed to determine whether the rates of biochemical recurrence-free survival (BRFS) are influenced by PSMA-based staging compared with that of conventional imaging among patients undergoing radical prostatectomy (RP), using real-world data and exploiting regional variation in the adoption of PSMA PET/CT across Denmark. Methods: This nationwide cohort study included men with high-risk PCa who underwent RP between 2016 and 2023. Patients were classified on the basis of whether they underwent PSMA PET/CT or conventional imaging before surgery. The primary outcome was BRFS, with overall survival as the secondary outcome. The outcomes were analyzed by inverse probability weighting and adjusted Cox proportional hazards regression analyses. Results: Among 3,279 eligible patients with high-risk PCa who underwent RP, 959 (29.3%) underwent preoperative PSMA PET/CT. This group had a higher 5-y BRFS rate than did the conventional imaging group (65.1%; 95% CI, 61.4%-68.7% vs. 61.1%; 95% CI, 58.9%-63.2%, respectively; weighted hazard ratio, 0.82; 95% CI, 0.70-0.96; P = 0.014). The difference was most pronounced in patients with Gleason scores of 8-10, with 62.5% in the PSMA PET/CT group (95% CI, 57.7%-67.2%) versus 48.9% in the conventional imaging group (95% CI, 44.9%-52.9%; hazard ratio, 0.61; 95% CI, 0.51-0.74; P < 0.001). Overall survival was also greater in the PSMA PET/CT group; however, the limited follow-up prohibited any firm conclusions. The main limitation of this study was its observational design. Conclusion: The use of PSMA PET/CT for high-risk PCa staging was associated with increased BRFS rates.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Mogensen AW, Torp-Pedersen C, Nørgaard M, et al. Biochemical Recurrence-Free Survival After Radical Prostatectomy in Patients with High-Risk Prostate Cancer: A Nationwide Study of PSMA PET/CT Versus Conventional Imaging. J Nucl Med. 2026. PMID: 41679924. doi:10.2967/jnumed.125.271423

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。